Cargando…

SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class

BACKGROUND: For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schernthaner, Guntram, Drexel, Heinz, Moshkovich, Evgeny, Zilaitiene, Birute, Martinka, Emil, Czupryniak, Leszek, Várkonyi, Tamás, Janež, Andrej, Ducena, Kristine, Lalić, Katarina, Tankova, Tsvetalina, Prázný, Martin, Smirčić Duvnjak, Lea, Sukhareva, Olga, Sourij, Harald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580491/ https://www.ncbi.nlm.nih.gov/pubmed/31208401 http://dx.doi.org/10.1186/s12902-019-0387-y

Ejemplares similares

Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)
por: Schernthaner, Guntram, et al.
Publicado: (2017)

Insulin Therapy in Adults with Type 1 Diabetes Mellitus: a Narrative Review
por: Janež, Andrej, et al.
Publicado: (2020)

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2020)

Perspectives of Patients with Insulin-Treated Type 1 and Type 2 Diabetes on Hypoglycemia: Results of the HAT Observational Study in Central and Eastern European Countries
por: Haluzik, Martin, et al.
Publicado: (2018)

Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs
por: Schernthaner, Guntram, et al.
Publicado: (2019)

The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
por: Czupryniak, Leszek, et al.
Publicado: (2021)

Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
por: Schernthaner, Guntram, et al.
Publicado: (2018)

High level of clinical inertia in insulin initiation in type 2 diabetes across Central and South-Eastern Europe: insights from SITIP study
por: Campbell, Matthew D., et al.
Publicado: (2019)

Hybrid Closed-Loop Systems for the Treatment of Type 1 Diabetes: A Collaborative, Expert Group Position Statement for Clinical Use in Central and Eastern Europe
por: Janez, Andrej, et al.
Publicado: (2021)

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
por: Schernthaner, Guntram, et al.
Publicado: (2017)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Expert Opinion: A Call for Basal Insulin Titration in Patients with Type 2 Diabetes in Daily Practice: Southeast European Perspective
por: Hancu, Nicolae, et al.
Publicado: (2021)

Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes
por: Jude, Edward B., et al.
Publicado: (2022)

Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2017)

The Role of Vaspin in the Development of Metabolic and Glucose Tolerance Disorders and Atherosclerosis
por: Dimova, Rumyana, et al.
Publicado: (2015)

Individualisierung der antihypertensiven Therapie bei Patient:innen mit Diabetes mellitus. Leitlinie der Österreichischen Diabetes Gesellschaft (Update 2023)
por: Saely, Christoph H., et al.
Publicado: (2023)

Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa
por: Giorgino, Francesco, et al.
Publicado: (2021)

Evaluation of the relationship between cardiac autonomic function and glucose variability and HOMA-IR in prediabetes
por: Dimova, Rumyana, et al.
Publicado: (2020)

Chronic Diabetic Complications: Current Challenges and Opportunities
por: Migdalis, Ilias N., et al.
Publicado: (2022)

SGLT2 Inhibitors and the Clinical Implications of Associated Weight Loss in Type 2 Diabetes: A Narrative Review
por: Janež, Andrej, et al.
Publicado: (2021)

Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?
por: Schernthaner, Guntram
Publicado: (2021)

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9)
por: Schernthaner, Guntram
Publicado: (2021)

Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies
por: Schernthaner, Guntram, et al.
Publicado: (2018)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
por: Kolesnik, Ewald, et al.
Publicado: (2022)

Risk Factors for Colorectal Adenoma – Acknowledging the Burden of NAFLD
por: Duvnjak, Marko, et al.
Publicado: (2019)

Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
por: Schernthaner, Guntram, et al.
Publicado: (2013)

The Link between Thyroid Autoimmunity, Depression and Bipolar Disorder
por: Jucevičiūtė, Neringa, et al.
Publicado: (2019)

Is vaspin related to cardio-metabolic status and autonomic function in early stages of glucose intolerance and in metabolic syndrome?
por: Dimova, Rumyana, et al.
Publicado: (2016)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
por: Wicik, Zofia, et al.
Publicado: (2022)

Diagnostic challenges of diabetic kidney disease
por: Vučić Lovrenčić, Marijana, et al.
Publicado: (2023)

Cure of Type 2 Diabetes by Metabolic Surgery? A Critical Analysis of the Evidence in 2010
por: Schernthaner, Guntram, et al.
Publicado: (2011)

New Drugs on the Block—Emerging Treatments for Nonalcoholic Steatohepatitis
por: Stojsavljevic-Shapeski, Sanja, et al.
Publicado: (2021)

Decrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery
por: Herz, Carsten T., et al.
Publicado: (2021)

The impact of FSH receptor polymorphism on time-to-pregnancy: a cross-sectional single-centre study
por: Zilaitiene, Birute, et al.
Publicado: (2018)

Relationship between Echocardiographic and Magnetic Resonance-Derived Measurements of the Thoracic Aorta in Turner Syndrome Patients
por: Krikščiūnienė, Rūta, et al.
Publicado: (2019)

Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer
por: Tankova, Tsvetalina, et al.
Publicado: (2022)

Hypoglycemia and Cardiovascular Risks
por: Frier, Brian M., et al.
Publicado: (2011)

Familial Hypercholesterolaemia in a Bulgarian Population of Patients with Dyslipidaemia and Diabetes: An Observational Study
por: Tankova, Tsvetalina, et al.
Publicado: (2020)

Associations between plasma protein, IgG and IgA N-glycosylation and metabolic health markers in pregnancy and gestational diabetes
por: Štambuk, Tamara, et al.
Publicado: (2023)

Different stability of miRNAs and endogenous control genes in archival specimens of papillary thyroid carcinoma
por: Pamedytyte, Daina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pjdksj39jtia7ls2ialafs6g7h